2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery — ISV-305  

Inflammation and Pain Associated With Cataract Surgery Clinical Trial

Official title: A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.

Clinical Trial Description

The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of ISV-305 (0.1% dexamethasone in DuraSite® 2) compared with Vehicle when dosed twice daily for 1 day prior to surgery, the day of surgery and 14 days post cataract surgery. ;

Related Conditions & MeSH terms

• Cataract
• Inflammation
• Inflammation and Pain Associated With Cataract Surgery

• NCT number: NCT03192150
• Study type: Interventional
• Source: Sun Pharmaceutical Industries Limited
• Status: Completed
• Phase: Phase 3
• Start date: January 3, 2018
• Completion date: November 18, 2019